VISEN Pharmaceuticals Receives IND Approval to Initiate Phase 2 Clinical Trial of TransCon ™ CNP in Achondroplasia (ACH) in China
Press release content from PR Newswire. The AP news staff was not involved in its creation. VISEN Pharmaceuticals Receives IND Approval to Initiate Phase 2 Clinical Trial of TransCon ™ CNP in Achondroplasia (ACH) in China January 7, 2021 GMT SHANGHAI, Jan. 7, 2021 /PRNewswire/ -- VISEN Pharmaceuticals, a biotech company committed to the treatment of endocrine-related diseases, introducing the world’s leading treatment methods and drugs into the China market and hoping to provide more Chines...
Source: apnews.com